At the Davos Forum, Sarah Friar, the CFO of OpenAI, announced that the company aims to claim a certain proportion of the research and development (R&D) gains achieved by customers through the utilization of its AI technology. This includes revenue from drug sales, as a means to transcend the constraints of the subscription-based business model.
